Introduction: In the northern region of Brazil, stomach cancer (SC) is the second most common malignant neoplasm among men and the fifth most frequent among women. The risk factors for SC have a multifactorial origin, including genetic, environmental, and even infectious components, especially infection by Helicobacter pylori. A better epidemiological understanding of the hospital morbidity and mortality rate due to SC may improve the therapeutic management of affected patients, according to the region's characteristics. Objectives: Analyze the profile of hospital deaths due to malignant neoplasm of the stomach in the metropolitan region of Belém between the years 2020 and 2024. Methods: This study is an observational, cross-sectional, and quantitative research with an epidemiological character. The analysis integrates data from the ICD-10 category C16, malignant neoplasm of the stomach, in the metropolitan area of Belém. The prevalence by sex, age group, and race/skin color, between the years 2020 and 2024, was also considered. The information was obtained through the Hospital Morbidity Declaration System (SIH/SUS) of the Department of Informatics of the Unified Health System (DATASUS). Authorization from the Research Ethics Committee was not required, as it does not involve patient samples or data. Results: A total of 1,778 hospitalizations due to gastric neoplasm were recorded, of which 464 resulted in death among hospitalized patients, referred to here as Deaths Among Hospitalized Patients (DAHP), corresponding to an overall mortality rate of 26.09%. During the analyzed period, this rate showed an upward trend, being highest in 2023 (29.2%) and lowest in 2020 (22.9%). Among municipalities, the highest DAHP rates were observed in Benevides (29.1%), Belém (26.6%), and Ananindeua (25.6%). In comparison, Santa Bárbara do Pará recorded the lowest incidence of DAHP (15.7%). Whereas, in the analysis of the age group, those with the highest DAHP included individuals over 80 years old (40%), 70-79 years old (27.5%), and 30-39 years old (26.4%). In contrast, the age group with the lowest occurrence of deaths was 10–19 years (20%), with no recorded deaths in the 0–9 years group. Regarding sex, the most affected gender was female (26.4%), with a similar incidence observed in males (26.0%). In terms of race/skin color, individuals with pardo skin were the most affected (26.1%), followed by those with white skin (23.8%) and black skin (17.3%). Conclusion: In summary, the data analysis made it possible to identify that the group of hospitalized patients most susceptible to mortality from malignant neoplasm of the stomach consists of women, individuals with pardo skin, people aged 80 years or older, and those hospitalized in Benevides. Thus, due to the increase in the DAHP rate during the analyzed years, this study highlights a warning for health management planning. For this reason, the collected information serves as a basis for the development of public policies aimed at reducing hospital morbity and mortality, with a focus on prevention, early diagnosis, and improvement in the quality of healthcare services provided, especially for high-risk populations.
It is with great enthusiasm that we present the Annals of the Oncology International Symposium 2025, an event that continues to solidify its significance in the oncology landscape of northern Brazil. Held in Belém, Pará, Oncology 2025 centered around the theme "The cancer control challenge: better knowing it to best facing it," dedicating itself to exploring the latest frontiers in cancer treatment and prevention.
This year, the symposium provided a deep dive into the essential role of knowledge in the fight against cancer, presenting new perspectives and scientific advancements across various areas of oncology. Renowned global experts gathered to share their most recent research and innovative approaches, offering participants a comprehensive view of the challenges faced by healthcare professionals and patients worldwide.
Presentations and discussions during the event focused on critical topics such as the use of new technologies, advancements in personalized therapies, and more effective prevention strategies. Additionally, particular attention was given to the unique challenges faced by the Amazon region, with efforts aimed at developing region-specific solutions to meet local needs.
Beyond being a high-caliber academic event, Oncology 2025 stood out as a moment for integration and professional networking, with the warm hospitality of the city of Belém offering participants a unique experience. This event became a platform for exchanging ideas, where science, culture, and humanity came together in pursuit of a common goal: to improve cancer control both in Brazil and globally.
This collection of abstracts and articles presented during the event reflects the ongoing dedication to research and the development of innovative solutions, highlighting the importance of collaboration and shared knowledge in the fight against cancer.
General Submission Guidelines:
The presenting author, who does not have to be the first author, must be registered for Oncology 2025.
Each abstract may have up to 10 authors, including the main author and co-authors.
Only original, unpublished work will be accepted.
Submissions must be related to oncology. However, project descriptions, work proposals, experience reports, and literature reviews will not be considered.
Clinical case reports are allowed, provided the abstract addresses scientific questions, details clinical observations, and includes primary scientific data.
The abstract must be written in English, but presentations may be given in Portuguese.
Abstracts must be between 300 and 500 words.
Comissão Organizadora
Comissão Científica
See Annals of Oncology 2023 at:
https://www.even3.com.br/anais/oncology-2023-international-symposium/
Complete tool for submission, evaluation and publication of proceedings for scientific events.
